Other technologies can be combined with the RFID chip to provide an extraordinary range of silent commerce services. Small microsensors that monitor the environment around them are currently being tested. Want to make sure the fish is fresh, the beer has never been warmed or the equipment has not been exposed to moisture? Scan the chip and the sensors will tell you what the product has been exposed to at any place along the value chain. Or, using new display technologies such as electronic ink, manufacturers can dynamically change the text or writing on the package to provide useful safety and quality information about the product.
Die Verbesserung der Compliance ist für alle Medizinalpersonen und insbesondere für die Patienten eine alltägliche Herausforderung. Es gilt, die Notwendigkeit einer Therapie einzusehen, mit der Therapiewahl sich anfreunden zu können und dann einen Therapieplan in den Alltag integrieren zu können – allenfalls mit einer lebenslangen Dauer. Willentliche und unwillentliche Non Compliance sind häufig; Studien berichten von bis zu 50 %. Die Apotheker, als letztes Glied in der Versorgungskette, sind in bester Position um den Patienten nach Motivation, Kenntnissen und Hindernissen zu befragen und maßgeschneiderte technische und motivationale Hilfe zu leisten. Unverzichtbar ist die eingehende Anwendungsinstruktion bei der Abgabe, damit allfällige eingeschränkte Fertigkeiten (Geschicklichkeit, Sehvermögen, Kognition) erkannt und Hilfe angeboten werden kann. Eine Vielzahl von Hilfsmitteln sowie neue Technologien können gezielt eingesetzt werden um auch die langfristige Befolgung eines Therapieplanes zu gewährleisten.
Every once in a while, a new "RFID Smart Blister" arrives on the scene, and the OtCM package from The Compliers Group in Netherlands is one such latest design. A new research study conducted by University Hospital Mainz in Germany found that, when testing another recently launched smart blister technology, only 82 out of 94 packages survived patient use and from those, just 80% to 95.7% of events accurately, or at all. Furthermore, these packages were tested by just removing 10 doses from the blister, presumably making the situation much worse had packages with 21, or 30 doses been tested in similar fashion.
Med-ic's 7-year experience with self-adhesive smart labels for medication blisters, and real-life, multi-year, multi-center clinical studies which demand an extremely high level of accuracy and reliability, has resulted in many designs yielding real-life package survival over 90 days in patients hands of better than 95%, and dose reporting accuracy of 99.6% or better, even with 14, 21, 30 and up to 42 doses per package. Med-ic smart labels are easy to apply, and are produced with non toxic conductive inks printed directly on paper labels.
Med-ic Blisters are designed to be better than 99.6% accurate in reporting dosing events, even when packages are handled in adverse, moist, or cold conditions. Validation data and references are available to qualified parties by contacting
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Adherence to therapies is a primary determinant of treatment success. Poor adherence attenuates optimum clinical benefits and therefore reduces the overall effectiveness of health systems.
“Medicines will not work if you do not take them” — Medicines will not be effective if patients do not follow prescribed treatment, yet in developed countries only 50% of patients who suffer from chronic diseases adhere to treatment recommendations. In developing countries, when taken together with poor access to health care, lack of appropriate diagnosis and limited access to medicines, poor adherence is threatening to render futile any effort to tackle chronic conditions, such as diabetes, depression and HIV/AIDS.
World's largest and most respected Market Research resource. Searchable database of market research reports incorporating all niche and top industries.
New international standards no longer require directly observed therapy for all tuberculosis (TB) patients, but state that practitioners must be capable of assessing adherence and addressing poor adherence. Massproduced electronic medication monitors, which record removal of medication from a container, could help overcome the problem of assessing treatment adherence accurately even in poor countries. Both health facilities and community workers could dispense drugs for self-administered treatment in medication monitors and retrieve the adherence record with inexpensive built-in displays. These devices could keep the adherence record from the beginning of therapy for managing patients who move. Pharmacists using medication monitors could provide surveillance of self-administered treatment prescribed by private physicians with less adherent patients referred to the health departments. Less adherent patients could be managed with focused counselling, directly observed therapy when necessary, and extensions in treatment duration. Removal of the directly observed therapy burden would encourage patients to seek free high-quality supervised pubic care and help expand effective TB treatment services. If resources saved by giving less directly observed therapy were focused on poorly adherent patients, medication monitor-based programmes could create less acquired drug resistance than overwhelmed treatment programmes that attempt but fail to give uninterrupted directly observed therapy to all patients.
The outcome of this study should help programs determine the most appropriate interventions. If evidence demonstrates, for example, that freezing occurs most commonly during vaccine transport, new procedures for conditioning of ice packs, or ice-free transport can be implemented. If there is a correlation between specific types of refrigerators and freezing, equipment replacement may be required or, alternatively, more attention given to the training of cold chain supervisors.
Sixty years after the introduction of effective chemotherapy, the World Health Organization (WHO) estimates, based on surveillance and survey data, that the number of new tuberculosis (TB) cases has reached 8.9 million in 2004, with an annual rate increase of 0.6%...
To assess adherence to intermittent directly observed treatment (DOT) during the 2-month intensive phase of tuberculosis (TB) treatment in south-west rural China.
To determine the frequency with which direct observation actually occurred within a district-level DOTS programme, and the association of treatment observation with treatment outcome under programme conditions.
Rifabutin was recommended in place of rifampin during treatment of HIV-related tuberculosis (TB) to facilitate concomitant potent antiretroviral therapy, but this approach has not been evaluated in a prospective study....
The purpose of this website is to present the status of development of a wide variety of portable electronic medication monitors that could be used to supervise the self-administered treatment of tuberculosis and perhaps AIDS. The discussion includes both commercially available devices and various designs of potential medication monitors, to allow investigators and funding sources to chose the optimal device for their needs and encourage inventors to develop improvements.
"This is the first study to ask the question, 'Are we gaining ground or losing ground in drug safety and improving patient safety in prescription drugs?' And I think, inescapably, the conclusion is that we're losing ground," said study lead author Thomas Moore, of the Institute for Safe Medication Practices, in Huntingdon Valley, Pa.
"This is a subject the public or health professionals just don't like to think about," Moore added. "Doctors don't like to think that what they're doing could be hurting patients. The pharmaceutical industry wants the public focused on benefits, and many people just want to believe this drug is going to help them. We need to focus on this problem. We can manage the risks of prescription drugs if we start to pay attention."
A slew of new technologies, ranging from RFID and printed electronics, through shape memory alloys to novel battery and display technologies, is enabling a new kind of packaging: smart packaging. Smart packaging relies on the use of chemical, electrical, electronic, or mechanical technology, or any combination of them to add numerous features and functions to packaging.
Smart packaging opens up new opportunities for enhancing inventory tracking, product safety and security, user friendliness and brand enhancement. Its impact is already being felt now in packaging for sectors as diverse as retailing, food and beverage, pharmaceuticals, cosmetics, military and toys. The use of smart packaging is also being pushed forward by changes in demographics and environmental concerns.
The report analyzes the market from all perspectives including materials suppliers, technology providers, printers and converters, product manufacturers and retailer/distributors. Companies mentioned in the report include:
* 3M * Aveso * Campbell * Coca Cola * CSIRO * Cypak * DuPont * DHL * Duracell * Heinz * IBM + Information Mediary * Intel, Konarka * Marks & Spencer * MeadWestvaco * PowerPaper * Proctor and Gamble * pSivida * Wal-Mart
For marketed products in the US, poor compliance with treatment regimens is estimated to cost the health care system around $100 billion each year. More than 100,000 patient deaths and one million hospital admissions each year, in addition to increased antibiotic resistance, are believed to be due to poor patient compliance. The cost of poor compliance in clinical trials is equally serious. Data from non-compliant patients can affect trial results to such an extent that they can make or break a candidate drug. While measures are in place to monitor compliance and avoid this (paper diaries and pill counting, for instance), these are far from perfect.
Accenture White Paper on U-commerce: Using microprocessors and sensors to make ordinary objects both intelligent and interactive, silent commerce opens up business opportunities and the possibility of new business models
Presented at the 2002 International Pharmaceutical Congress New York, April 2002
Introduction Health care costs threaten to overwhelm the economy. New technologies, pharmaceuticals and procedures add enormous costs to health care budgets. With advances in health care people are living longer, shifting the burden of the costs to an increasingly smaller percentage of the population. As population demographics shift to the older end of the spectrum, there is more opportunity for age-related chronic health problems to develop, further exacerbating the problem.
Information Mediary Corporation is dedicated to reducing health care costs by developing leading edge devices, systems, business models and technologies. This White Paper addresses the issue of patient non-compliance and outlines Information Mediary Corporation's solution. The Med-ic ECM (Electronic Compliance Monitor) is an electronic inventory monitoring system designed to address the issue of patient non-compliance with prescribed medication.
Vaccines are sensitive to heat and must be kept cold from the time they are manufactured until they are used. The equipment and people that keep vaccines cold during their journey are together called cold chain.
